Market revenue in 2023 | USD 4,697.0 million |
Market revenue in 2030 | USD 7,927.8 million |
Growth rate | 7.8% (CAGR from 2023 to 2030) |
Largest segment | Small molecule api |
Fastest growing segment | Small Molecule API |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule API, Small Molecule Drug Product |
Key market players worldwide | Wuxi AppTec Co Ltd, EQT Corp, Thermo Fisher Scientific Inc, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Boehringer Ingelheim, Labcorp Holdings Inc, Piramal Pharma Solutions, CordenPharma, Cambrex |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to small molecule innovator cdmo market will help companies and investors design strategic landscapes.
Small molecule api was the largest segment with a revenue share of 61.67% in 2023. Horizon Databook has segmented the China small molecule innovator cdmo market based on small molecule api, small molecule drug product covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the most technologically advanced countries in the Asia Pacific and significantly contributes to the region’s healthcare industry. China held a share of 22.78% in the Asia Pacific market in 2023.
The rising geriatric population and the presence of a large middle-income population are likely to boost the demand for small molecules. Moreover, the availability of low-cost labor is one of the major factors for pharmaceutical firms across the globe to outsource API development and manufacturing to China.
In addition, the growing number of clinical trials in the country is projected to create opportunities for the market. According to clinicaltrials.gov, as of February 2023, around 11,328 studies (recruiting, active, not recruiting, enrolling by invitation) were registered in China.
Horizon Databook provides a detailed overview of country-level data and insights on the China small molecule innovator cdmo market , including forecasts for subscribers. This country databook contains high-level insights into China small molecule innovator cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account